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The regulation of genes with important roles in embryonic 
development can be complex, involving multiple, often 
redundant enhancers, repressors, and insulators (1, 2). The 
genes may have a poised epigenetic state prior to their 
expression, and their activation or repression may involve 
positive or negative feed-forward loops. This complexity is 
likely to be amplified when the gene has functions in more 
than one tissue, given that the regulatory elements required 
for each are often interspersed and necessitate dynamic 
alterations in chromatin conformation (1, 2). The developing 
gonads comprise an interesting system in which to explore 
questions of gene regulation during development (3). Most of 
the cell lineages are bipotential, with the ability to give rise 
to cell types typical of either ovaries or testes, and many genes 
that become associated with male or female fate begin by 
being expressed at equivalent, although usually low, levels in 
supporting cell precursors of both XX and XY gonads (4–6). 
In mammals, the Sry gene encodes a protein that is tran-
siently expressed and initiates testis and subsequent male de-
velopment by triggering cells of the supporting cell lineage to 
differentiate into Sertoli rather than granulosa cells typical of 
ovaries (7). Sox9, the main target of SRY, is critical for the 
differentiation of Sertoli cells and then functions along with 
other transcription factors, notably Sox8 and then Dmrt1, for 
their maintenance (4–6). Both gain- and loss-of-function 
studies in mouse and human demonstrate that Sox9 plays a 
key role in testis determination (8–13). Notably, humans het-
erozygous for null mutations develop campomelic dysplasia 
(CD) [Online Mendelian Inheritance in Man (OMIM) entry 
114290] (11), a severe syndrome where 70% of XY patients 
show female development (12, 13). 
Sox9 functions in many embryonic and adult cell types 
(14), and genetic and molecular evidence suggests that its reg-
ulatory region is spread over at least a 2 Mb gene desert 5′ 
to the coding sequence (15). The only enhancer known to be 
relevant for expression in Sertoli cells was TES, a 3.2-kb ele-
ment mapping 13 kb 5′, and its 1.4-kb core, TESCO (16). Tar-
geted deletion of TES or TESCO reduced Sox9 expression 
levels in the early and postnatal mouse testis to about 45% of 
normal but did not result in XY female development (17). We 
therefore used several unbiased approaches to systematically 
screen for additional gonad enhancers upstream of mouse 
Sox9. We first made use of DNaseI-seq data obtained with 
embryonic day 13.5 (E13.5) and E15.5 sorted Sertoli cells (18). 
From 33 putative enhancers, we chose only those positive at 
both stages for in vivo validation by transgenic assays (14 en-
hancers) (Fig. 1A and fig. S1). In parallel, we carried out 
ATAC-seq on XY and XX gonads, which permitted the use of 
fewer sorted cells at E10.5, an early bipotential stage, and 
E13.5, when gonadal sex is already determined (figs. S1 and 
S2 and methods). Most putative enhancers discovered by 
DNaseI-seq were evident in the E13.5 XY ATAC-seq data; 
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however, we used this to include two more in the in vivo 
screen: enhancer 1 (Enh1) and Enh14 (Fig. 1A and fig. S1). 
Chromatin immunoprecipitation-seq (ChIP-seq) was also 
performed for H3K27ac, a histone modification that marks 
active enhancers (fig. S1). 
All 16 putative enhancers were cloned upstream of an 
hsp68 minimal promoter and the reporter gene LacZ and 
used to generate transgenic mice (2, 19) (table S1). For initial 
screens, we performed transient analyses at E13.5. Twelve 
failed to give any gonadal β-galactosidase (β-Gal) activity, alt-
hough many showed staining in other tissues in which Sox9 
is normally expressed, such as chondrocytes, brain, and spi-
nal cord (fig. S3). The remaining four showed gonad expres-
sion, and these constructs were reinjected to generate stable 
lines in order to better study their activity in both males and 
females during development. Enh8 [672 base pairs (bp) long, 
838 kb 5′] conferred robust β-Gal activity in the ovary, 
whereas it was barely present in the testis at E13.5 (Fig. 1A 
and fig. S4B). This may be due to Enh8 being taken out of its 
original genomic context; notably, ATAC-seq reveals a much 
stronger peak in granulosa cells compared to Sertoli cells (fig. 
S4A). 
In contrast, Enh14 (1287 bp long, 437 kb 5′) showed ro-
bust testis-specific β-Gal activity (Fig. 1A and fig. S5B). 
DNaseI-seq, ATAC-seq, and H3K27ac ChIP-seq all suggest 
that this enhancer is active and open only in Sertoli cells (figs. 
S1 and S5A). To test this candidate, we used genome editing 
to delete Enh14. However, Enh14 deletion did not alter ex-
pression of Sox9, its target gene Amh, or Foxl2, a marker of 
granulosa cells, in E13.5 XY gonads (fig. S5D), indicating that 
Enh14 has a redundant role, at least in the embryo. Enh32 
(970 bp long, 10 kb 5′) is also testis-specific, but very weak 
and restricted to a domain close to the mesonephros (Fig. 1A 
and fig. S6, B and C). ATAC-seq, DNaseI-seq, and H3K27ac 
ChIP-seq data suggest that this is a Sertoli cell enhancer, alt-
hough weak peaks were seen in the granulosa cell samples 
(figs. S1 and S6A). 
The remaining enhancer, Enh13 (557 bp long, 565 kb 5′), 
is highly conserved among mammals and located toward the 
distal 5′ end of a 25.7-kb region in mice showing conserved 
synteny with a 32.5-kb region upstream of human SOX9 
termed XY SR, whose deletion is associated with sex reversal 
(20) (Fig. 1, A and B, and fig. S1). Enh13 shows the strongest 
Sertoli cell–specific peak within this region, in both the 
DNaseI-seq and ATAC-seq data. H3K27ac ChIP-seq data mark 
Enh13 as active in both Sertoli and granulosa cells, which 
may support the observation that some transgenic lines also 
exhibit β-Gal activity in the ovary (Fig. 1C and figs. S1 and 
S7A). β-Gal expression is clearly within Sertoli and granulosa 
cells (fig. S7C). ATAC-seq data from E10.5 genital ridges show 
that Enh13 is not open at this stage, irrespective of chromo-
somal sex (Fig. 1B and fig. S1), suggesting that it opens coin-
cident with specification of the supporting cell lineage from 
SF1-positive cells of the coelomic epithelium (5). 
Genome editing was used to derive mice homozygous for 
deletions of Enh13. Irrespective of whether this was carried 
out on a TES mutant background or by itself it always led to 
XY female development (Fig. 2 and figs. S8 to S10). The latter 
result was surprising, because if TES accounts for 55% of Sox9 
expression in early Sertoli cells, any additional enhancer(s) 
should not account for more than 45%, and, when deleted, 
levels of Sox9 would remain higher than the threshold of 
about 25% below which sex reversal might be expected (17). 
Nevertheless, at embryonic stages, whereas XY Enh13+/− em-
bryos still undergo normal testis development, XY Enh13−/− 
embryos produce ovaries indistinguishable from those of XX 
wild-type embryos, with no signs of testis cords or a coelomic 
vessel (Fig. 2, B and C, and fig. S10). Immunofluorescence 
analysis for SOX9 and FOXL2 of E13.5 and 6-week-old XY 
Enh13+/− and Enh13−/− gonads showed that the former are still 
testes whereas the latter are fully sex-reversed ovaries (Fig. 
2C and fig. S10D). Similar analysis of XX Enh13-deleted gon-
ads did not show any obvious phenotype (fig. S11). 
The Enh13 deletion was generated on a C57BL/6J genetic 
background, which is sensitized toward XY female sex rever-
sal (21). To test the strength of the deleted allele, we therefore 
backcrossed it onto a mixed C57BL/6J × CBA background. As 
before, XY heterozygotes presented as normal fertile males 
whereas homozygotes showed full male-to-female sex rever-
sal (fig. S12). 
We could detect no difference in gonadal phenotypes be-
tween Enh13−/−:TES+/+ and Enh13−/−:TES−/− embryos or mice, 
suggesting that homozygosity for the Enh13 deletion alone 
reduced Sox9 levels well below the critical threshold required 
for testis development, which had been determined at E13.5 
(17) (figs. S8 and S10). However, examining levels of gene ex-
pression at this stage when there is sex reversal will be unin-
formative because factors such as WNT4 and FOXL2 repress 
Sox9 once ovary development begins (5). We therefore ana-
lyzed Sox9, Sry, Sf1, and Foxl2 mRNA at E11.5, during the 
brief period when gonadal sex is being determined. qRT-PCR 
revealed that XY Enh13+/− and Enh13−/− genital ridges ex-
pressed 58 and 21% of the wild-type levels of Sox9 mRNA, 
whereas XY TES+/− and TES−/− genital ridges showed 55 and 
50%, respectively (Fig. 3A). In control genital ridges, XX con-
tained 18% of the Sox9 mRNA levels found in XY (Fig. 3A). 
Therefore, E11.5 XY Enh13−/− gonads express Sox9 at levels 
close to those of XX gonads at the same stage, explaining the 
observed complete sex reversal. Deleting one or two copies of 
TES had relatively little effect at E11.5, especially compared 
to at E13.5, and is in contrast to the results with Enh13 dele-
tions at E11.5 (Fig. 3A) (17). This again supports the conclu-
sion that Enh13 plays a more significant role than TES during 
o
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early gonadal development. 
Sry expression is normally down-regulated as SOX9 levels 
increase, but it can persist if testis differentiation fails (22, 
23). This is consistent with a direct or indirect repressive ef-
fect of SOX9 on Sry. At E11.5, Sry mRNA levels were higher 
compared to wild-type in both Enh13+/− and Enh13−/− XY gon-
ads (168 and 152%, respectively) (Fig. 3B). In contrast, the 
TES deletion did not significantly alter Sry expression (Fig. 
3B), which is expected because Sertoli cell differentiation is 
proceeding in these mutants. SF1 is known to interact first 
with SRY and later with SOX9 to regulate Sox9 expression 
levels and also many of their downstream target genes (16). 
We found no significant changes in levels of Sf1 mRNA in any 
of the enhancer deletions at E11.5 (Fig. 3C). Using Foxl2 as an 
early marker of granulosa cell differentiation (24), mRNA lev-
els were 3.6-fold higher in XX than XY wild-type gonads at 
E11.5 (Fig. 3D). Compared to the latter, Enh13+/− and Enh13−/− 
XY gonads showed a 2-fold and 3-fold increase, respectively, 
with the homozygotes having very close to XX control levels. 
Therefore, Enh13−/− XY gonads reveal an early commitment 
to the ovarian pathway. 
There was a 30 to 50% decrease in Sox9 mRNA levels in 
E11.5 XX Enh13−/− gonads compared to wild type, reflected by 
reduced immunofluorescence for SOX9 protein (fig. S11). 
These data indicate that Enh13 also plays a role in the very 
early expression of Sox9 in the XX gonad, consistent with 
both the small peak seen with ATAC-seq and with occasional 
reporter activity in the transgenic mouse assays (Fig. 1, B and 
C, and fig. S7). 
The sequence of Enh13 is highly conserved among mam-
mals (Fig. 1B) and contains consensus binding sites for tran-
scription factors known to regulate early gonad development 
and sex determination (fig. S13) (6). Mouse Enh13 contains a 
single consensus SRY binding site as well as a SOX9 site to 
which SRY can also bind (Fig. 4A and fig. S13). ChIP-qPCR on 
E11.5 gonads dissected from Sry-Myc transgenic embryos was 
performed using a specific antibody against the MYC tag (22). 
There was an 11-fold enrichment in SRY-MYC–positive versus 
negative gonads with primers spanning the SOX9 consensus 
site and a sixfold enrichment with primers spanning the SRY 
site, whereas primers against the strongest SRY binding site 
in TESCO (22) showed fivefold enrichment (Fig. 4, A and B). 
This reveals the strong binding of SRY to Enh13 at E11.5, with 
a preference for the SOX9 consensus site, possibly due to the 
adjacent SF1 binding site. Preferential binding of SRY to 
Enh13 over TESCO at E11.5 supports the hypothesis that the 
former is more critical because it initiates up-regulation of 
Sox9 while the latter is secondary. 
ChIP assays revealed SOX9 to be bound at similar levels 
to both Enh13 and TESCO in cells from E13.5 testes (Fig. 4C). 
In addition, SOX9 ChIP-seq data using bovine embryonic tes-
tis (25) revealed a strong peak localizing to the conserved 
syntenic region of Enh13 (537 bp long, 570 kb 5′) (Fig. 4D). 
This suggests that, like TES, Enh13 is used by SOX9 to auto-
regulate its expression, and that this interaction is conserved 
in mammals. Unlike several other gonadal enhancers, Enh13 
appears well conserved, has a clear role in mice to initiate up-
regulation of Sox9 expression, in response to SRY activity, 
and it may contribute to its maintenance. This makes it very 
likely to play a similar role in humans given its location 
within the XY SR region (20, 26). If so, heterozygosity for 
Enh13 deletions in humans should mimic heterozygosity for 
null mutations in SOX9, with XY female sex reversal occur-
ring in about 70% of cases but perhaps without other CD phe-
notypes. 
It is clear from our data and that of others that the up-
stream regulatory region of Sox9 is very complex. Our screens 
using gonadal cells revealed 33 potential enhancers distrib-
uted over 1.5 Mb. Transgenic assays used to test the most 
promising 16, revealed four that gave expression in the gon-
ads, whereas the majority did not. This “hit rate” of 25% 
agrees with some other studies (19) and merits caution in in-
terpreting data based solely on accessibility of chromatin and 
histone marks. However, some are bona fide enhancers in 
other locations; for example Enh29, mapping about 70 kb 5′, 
is equivalent to “SOM”, an enhancer active in many tissues 
except the gonads (27). Others may have distinct roles; indeed 
Enh11 contains a putative CTCF binding site. In addition, sev-
eral putative enhancers, notably Enh4, 5, 8, and 9, appear 
open in both granulosa and Sertoli cells, with Enh8 even 
more so in the former. These could contribute to the low level 
of Sox9 seen in supporting cell precursors, but they may also 
represent sequences required to repress Sox9, which might 
not be detected by transgenic reporter assays. 
The notion of redundancy or “shadow enhancers” within 
a regulatory region is well established (28, 29), and recent 
data suggest that deletion of single, even “ultraconserved” en-
hancers from developmentally important genes can have at 
most subtle if not undetectable effects (30, 31). It is therefore 
remarkable to see that deleting Enh13 alone phenocopies the 
loss of Sox9 itself within the supporting cell lineage (9, 32). 
Substantial evidence points to the time-dependent action of 
SRY on Sox9. If Sox9 fails to reach a critical threshold within 
a few hours, then ovary-determining/anti-testis factors, such 
as Wnt signaling, accumulate to a sufficient level to repress 
Sox9 and make it refractory to male-promoting factors, in-
cluding SRY, even though expression of the latter persists in 
XY gonads when Sertoli cells fail to differentiate (33). We sug-
gest that Enh13 is an early-acting enhancer, such that without 
it Sox9 transcription fails to increase to a level where the 
other enhancers can act before the gene is silenced. It is only 
later that TES, and perhaps other enhancers such as Enh14, 
and Enh32, begin to act in a more redundant fashion, alt-
o
n








First release: 14 June 2018  www.sciencemag.org  (Page numbers not final at time of first release) 4 
 
hough it is conceivable that each has a major role to play dur-
ing distinct phases of Sertoli cell development from the fetal 
to the adult testis. It will be of interest to determine how 
Enh13 activity cascades into the recruitment of the other en-
hancers. 
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Fig. 1. Enh13 is a testis-positive enhancer of Sox9 located within the XY SR region. (A) A schematic 
representation of the gene desert upstream of the mSox9 gene and the locations of the putative enhancers 
identified by ATAC-seq and DNaseI-seq that were screened in vivo using transgenic reporter mice. Enhancers 
that did not drive gonad expression of LacZ are shown in gray. Enhancers that drove testis-specific and ovary-
specific LacZ expression are shown in blue and pink, respectively. The mouse regions that show conserved 
synteny with the human XY SR and REV SEX are depicted in green and purple boxes, respectively. (B) Enh13 
(gray box) is located at the 5′ side of the 25.7-kb mouse equivalent XY SR locus (black rectangular box). 
DNaseI-seq (black) on E15.5 and E13.5 XY sorted Sertoli cells and ATAC-seq on E13.5 sorted Sertoli cells 
(blue) and granulosa cells (purple), as well as E10.5 sorted somatic cells, at Enh13 genomic region are 
presented. Peaks correspond to nucleosome depleted regions, and are marked by black box if they are 
significantly enriched compared to flanking regions as determined by MACS, and present in at least two 
biological replicates. The gray box overlaying each peak indicates the cloned fragment. Green lines represent 
sequence conservation between mouse, human, rhesus, cow, and chicken (sequence conservation tracks 
obtained from UCSC). (C) β-Gal staining (blue) of E13.5 testes and ovaries from two representative 
















Fig. 2. Deletion of Enh13 leads to complete XY male-to-female sex reversal. (A) A schematic representation 
of the locations of Enh13 and TES upstream of Sox9. Turquoise and purple arrows represent the external and 
internal sgRNAs used to delete Enh13. Black arrows represent the PCR primers used to genotype Enh13 deleted 
embryos and mice. (B) Bright-field pictures and hematoxylin and eosin (H&E)–stained sections of E13.5 XY 
Enh13+/+, Enh13+/−, and Enh13−/− and XX Enh13+/+ gonads. (C) Immunostaining of E13.5 gonads from XY wild 
type, Enh13+/−, and Enh13−/− and XX wild type. Gonads were stained for Sertoli marker SOX9 (green), granulosa 
marker FOXL2 (red), and 4′,6-diamidino-2-phenylindole (DAPI) (blue). Sex-reversed gonads are 
indistinguishable from wild-type XX gonads, while the heterozygous deletion does not appear to alter testis 

















Fig. 3. Enh13 regulates the expression of the Sox9 gene in vivo. (A to D) Real-
time quantitative PCR of genes involved in male (Sox9, Sry, and Sf1) and female 
(Foxl2 and Sf1) sex determination in XY Enh13 deleted and TES deleted gonads at 
E11.5 (18 tail somites). Data are presented as mean 2−ΔΔCt values, normalized to the 
housekeeping gene Hprt. Sample size represents the number of individuals and is 
indicated below each genotype. Error bars show SEM of 2−ΔΔCt values. P value is 
presented above the relevant bars (unpaired, two-tailed t test on 2−ΔΔCt values; *P ≤ 
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Fig. 4. Enh13 is bound by SRY and SOX9 in vivo. (A) A schematic representation of the location of the primers 
used for ChIP experiments in Enh13. (B) ChIP-qPCR assay of E11.5 mouse genital ridge following 
immunoprecipitation with anti-cMYC antibody. Data are presented as fold enrichment of SRY-MYC–positive 
relative to SRY-MYC–negative genital ridges, meaning that values greater than 1 represent specific 
enrichment. The primers used span the putative SRY binding site in Enh13, TESCO [around SRY R6 site; see 
(16)] and a negative control region on Chr11. Data are the mean ± SD (n = 2); ****P < 0.0005 (Student t test). 
(C) ChIP-qPCR assay of E13.5 mouse testes following immunoprecipitation with anti-SOX9 antibody. The 
primers used span the putative SOX9 binding site in Enh13, TESCO [around SOX9 R1 site; see (16)] and a 
negative control region on Chr11. Data are the mean ± SD (n = 3); ****P < 0.0005 (Student t test). (D) ChIP-
seq with anti-SOX9 antibody using E90 fetal bovine testis. The bovine Enh13 is indicated by the gray box (at 
Cow Bostau8 chr19: 60,063,628-60,064-165). The star represents the peaks with FDR <0.05 in the two bovine 
datasets. y-axis numbers represent counts. The input tracks represent sequencing reads of chromatin input. 












Sox9Sex reversal following deletion of a single distal enhancer of 
Sekido, Francis Poulat, Danielle M. Maatouk and Robin Lovell-Badge
Nitzan Gonen, Chris R. Futtner, Sophie Wood, S. Alexandra Garcia-Moreno, Isabella M. Salamone, Shiela C. Samson, Ryohei






This article cites 44 articles, 10 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
registered trademark of AAAS.
 is aScienceAmerican Association for the Advancement of Science. No claim to original U.S. Government Works. The title 
Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee 
(print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement ofScience 
o
n
 June 22, 2018
 
http://science.sciencem
ag.org/
D
ow
nloaded from
 
